- Pin
- #Over 100 Companies Hold Over 830,000 BTC#
According to reports as of June 19, more than 100 companies collectively hold over 830,000 BTC, worth about $86.476 billion.
💬 Do you think Bitcoin will become a new norm for corporate asset allocation? How might this impact Bitcoin’s price? What’s your recent BTC trading strategy? Post to share your price predictions, market analysis, and strategies with us using the topic tag!
🎁 Meanwhile, Gate’s BTC Staking event is in full swing! Simply stake your BTC and earn up to 3% APY. Click the link to start staking and enjoy your earnings: https://ww - 🏁 Gate Red Bull Racing Tour 2025 In Full Swing!
Up to now, the total trading volume exceeded $2 billion, with top trader trading volume nearing $200 million
Join the race now & fuel your trades for real-world rewards:
✅ 5,000 GT Prize Pool
✅ VIP Seat at an F1 Grand Prix
✅ Futures Vouchers for New Signups
Start your engines & trade fast
Top the leaderboards. The Race is ON!
👉 Go Now: www.gate.com/competition/f1rb/s1
#GateRedBullRacingTour# - 📢 Gate releases its latest Reserve Audit Report!
💰 Total reserves: $10.453B
🟢 Excess reserves: $1.96B — ensuring full coverage and extra security for user assets.
Gate continues to uphold 100% proof-of-reserves and full transparency.
🔗 Read the full report: https://www.gate.com/zh/announcements/article/45617
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.